ROS1 Fusion is an inclusion criterion in 28 clinical trials for non-small cell lung carcinoma, of which 26 are open and 2 are closed. Of the trials that contain ROS1 Fusion and non-small cell lung carcinoma as inclusion criteria, 5 are phase 1 (5 open), 3 are phase 1/phase 2 (3 open), 19 are phase 2 (17 open), and 1 is phase 2/phase 3 (1 open) [5].

Cabozantinib, ceritinib, crizotinib, entrectinib, lorlatinib, and pembrolizumab have evidence of efficacy in patients with ROS1 Fusion in non-small cell lung carcinoma [5].

ROS1 Fusion is an inclusion criterion in 19 clinical trials for malignant solid tumor, of which 17 are open and 2 are closed. Of the trials that contain ROS1 Fusion and malignant solid tumor as inclusion criteria, 5 are phase 1 (3 open), 3 are phase 1/phase 2 (3 open), and 11 are phase 2 (11 open) [5].

ROS1 Fusion is an inclusion criterion in 4 clinical trials for melanoma, of which 3 are open and 1 is closed. Of the trials that contain ROS1 Fusion and melanoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (2 open) [5].

ROS1 Fusion is an inclusion criterion in 4 clinical trials for colorectal carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ROS1 Fusion and colorectal carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 2 (2 open) [5].

ROS1 Fusion is an inclusion criterion in 3 clinical trials for cancer, of which 2 are open and 1 is closed. Of the trials that contain ROS1 Fusion and cancer as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (0 open) [5].

ROS1 Fusion is an inclusion criterion in 2 clinical trials for lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ROS1 Fusion and lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

ROS1 Fusion is an inclusion criterion in 2 clinical trials for breast carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ROS1 Fusion and breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

ROS1 Fusion is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ROS1 Fusion and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

ROS1 Fusion is an inclusion criterion in 2 clinical trials for bladder carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ROS1 Fusion and bladder carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

ROS1 Fusion is an inclusion criterion in 2 clinical trials for prostate carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ROS1 Fusion and prostate carcinoma as inclusion criteria, 2 are phase 1 (2 open) [5].

ROS1 Fusion is an inclusion criterion in 2 clinical trials for anaplastic large cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain ROS1 Fusion and anaplastic large cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

ROS1 Fusion is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain ROS1 Fusion and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [5].

ROS1 Fusion is an inclusion criterion in 1 clinical trial for lung adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 Fusion and lung adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ROS1 Fusion is an inclusion criterion in 1 clinical trial for non-squamous non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 Fusion and non-squamous non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ROS1 Fusion is an inclusion criterion in 1 clinical trial for mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 Fusion and mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [5].

ROS1 Fusion is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 Fusion and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ROS1 Fusion is an inclusion criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ROS1 Fusion and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

ROS1 Fusion is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 Fusion and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ROS1 Fusion is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 Fusion and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ROS1 Fusion is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 Fusion and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ROS1 Fusion is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 Fusion and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ROS1 Fusion is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 Fusion and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ROS1 Fusion is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 Fusion and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ROS1 Fusion is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 Fusion and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ROS1 Fusion is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ROS1 Fusion and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

ROS1 Fusion is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains ROS1 Fusion and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [5].

ROS1 Fusion is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 Fusion and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ROS1 Fusion is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 Fusion and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ROS1 Fusion is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 Fusion and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ROS1 Fusion is an inclusion criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 Fusion and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ROS1 Fusion is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 Fusion and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ROS1 Fusion is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 Fusion and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ROS1 Fusion is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 Fusion and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ROS1 Fusion is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 Fusion and hepatocellular carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ROS1 Fusion is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ROS1 Fusion and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

ROS1 Fusion is an inclusion criterion in 1 clinical trial for mucosal melanoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 Fusion and mucosal melanoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ROS1 Fusion is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 Fusion and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [5].

ROS1 Fusion is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 Fusion and renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ROS1 Fusion is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 Fusion and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].